Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series

BACKGROUND: Regorafenib is a therapeutic alternative for patients with metastatic colorectal cancer (MCRC) resistant to conventional therapies. The reported toxicity is relevant and there is no data on Latin American patients. The objective was to evaluate the overall survival (OS), progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Leal, José Luis, Briones, Juan, Herrera, María Elisa, Müller, Bettina, Nervi, Bruno, Mondaca, Sebastián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214673/
https://www.ncbi.nlm.nih.gov/pubmed/30483355
http://dx.doi.org/10.3332/ecancer.2018.875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214673/
https://www.ncbi.nlm.nih.gov/pubmed/30483355
http://dx.doi.org/10.3332/ecancer.2018.875

Ejemplares similares